About JITC

Reviewer_2.png
The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Become a Reviewer

For_Authors.png
Help enrich communication and advance scientific understanding in cancer immunotherapy.

For Authors

Editor.png
JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

From the Editors

Collections.png
Readers have the opportunity to view JITC's special editions and theme-focused collections.

JITC Collections




Get to Know JITC's Leadership

JITC is pleased to welcome Michael T. Lotze, MD as the journal's Incoming Editor-in-Chief. He is working with Interim Editor-in-Chief, James L. Gulley, MD, PhD, FACP, throughout 2024 as leadership is transferred. In addition, Sjoerd H. van der Burg, PhD has been promoted to Deputy Editor-in-Chief after a tremendous year of support in an interim capacity in 2023. Read more about this phenomenal group of leaders. 

Get the chance to meet these editors at conferences throughout the year. From Barcelona, Spain to San Diego, CA, our editors will be available to meet with you and learn about your research. Check back for more information on Meet-the-Editor opportunities in 2024. 




JITC Awards

Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.

Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.

The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.



APC Discounts

As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 35 percent discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2024. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author. 

JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. 

For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.



Highly Accessed Articles

What is the article Altmetric Attention Score?


Altmetric_Score_donut.pngIndicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

CARs are sharpening their weapons

Article has an altmetric score of 385
Alice Pievani, Marta Biondi, Sarah Tettamanti, Andrea Biondi, Gianpietro Dotti and Marta Serafini


 

Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity

Article has an altmetric score of 385
Quentin G Wright, Debottam Sinha, James W Wells, Ian H Frazer, Jazmina L Gonzalez Cruz and Graham Robert Leggatt


 

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity

Article has an altmetric score of 385
Emmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu, Rebekka Schairer, Hildegard Keppeler, Anton Wesle, Hannes Schmid, Anita Schmitt, Brigitte Neuber, Daniela Chmiest, Silvia Podavini, Melanie Märklin, Boris Klimovich, Michael Schmitt, Fulya Korkmaz, Claudia Lengerke, Corina Schneidawind and Dominik Schneidawind


 

Browse the Current Issue